(RTTNews) - Newron Pharmaceuticals (NP5.DE) said the FDA has provided written feedback regarding the clinical hold affecting U.S. sites in its Phase 3 ENIGMA-TRS 2 study of evenamide, and the company is preparing a response.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.